The MOPETT Trial took sub-massive PE patients and randomized them to half-dose tPA vs. standard care. No bleeds in either group. 41% ARR of pulmonary hypertension at 28 months.
Study Description from the Author
Does this change your game?
A new trial using a similar protocol showed benefit without complications (Clinical Cardiology Volume 37, Issue 2, pages 78–82, February 2014)
Latest posts by Scott Weingart (see all)
- EMCrit Podcast 242 – ED Nephrology with Joel Topf aka KidneyBoy - March 9, 2019
- EMCrit Podcast 241 – Sepsis Update 2019 - February 21, 2019
- EMCrit Podcast 240 – Renal Compartment Syndrome & It's all about the Venous Side and We've Been Fracking it up for Years - February 10, 2019